Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Laninamivir: Difference between pages

{{Short description|Chemical compound}}

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 462088695

| IUPAC_name = (4S'',''5''R'',6''R'')-5-acetamido-4-carbamimidamido-6-[(1''R'',2''R'')-3-hydroxy-2-methoxypropyl]-5,6-dihydro-4''H''-pyran-2-carboxylic acid

| image = Laninamivir.svg

| width = 200px

| tradename =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 203120-17-6

| ATC_prefix = J05

| ATC_suffix = AH04

| ChEMBL_Ref = {{ebicite|correct|EBI}}

| C=13 | H=22 | N=4 | O=7

[[File:Inavir.jpg|thumb|Inavir]]

'''Laninamivir''' ('''CS-8958''') is a [[neuraminidase inhibitor]] that is a drug used for the treatment and [[prophylaxis]] of [[Influenzavirus A]] and [[Influenzavirus B]].<ref name="pmid18955520">{{cite journal | vauthors = Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S | title = CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity | journal = Antimicrobial Agents and Chemotherapy | volume = 53 | issue = 1 | pages = 186–192 | date = January 2009 | pmid = 18955520 | pmc = 2612152 | doi = 10.1128/AAC.00333-08 }}</ref> It is currently in Phase III clinical trials.<ref name="pmid19067613">{{cite journal | vauthors = Hayden F | title = Developing new antiviral agents for influenza treatment: what does the future hold? | journal = Clinical Infectious Diseases | volume = 48 Suppl 1 | issue = S1 | pages = S3-13 | date = January 2009 | pmid = 19067613 | doi = 10.1086/591851 | series = 48 | doi-access = free }}</ref> It is a long-acting neuraminidase inhibitor administered by nasal inhalation.<ref name="samson review">{{cite journal | vauthors = Samson M, Pizzorno A, Abed Y, Boivin G | title = Influenza virus resistance to neuraminidase inhibitors | journal = Antiviral Research | volume = 98 | issue = 2 | pages = 174–185 | date = May 2013 | pmid = 23523943 | doi = 10.1016/j.antiviral.2013.03.014 }}</ref>

Laninamivir was approved for influenza treatment in Japan in 2010 and for prophylaxis in 2013. It is currently marketed under the name '''Inavir''' by Daiichi Sankyo. Biota Pharmaceuticals <ref>{{Cite web |url=http://www.biotapharma.com/ |title=Aviragen Therapeutics - Home |access-date=2013-04-12 |archive-date=2016-04-17 |archive-url=https://web.archive.org/web/20160417124102/http://www.biotapharma.com/ |url-status=dead }}</ref> and Daiichi Sankyo co-own Laninamivir. On 1 April 2011, BARDA awarded up to an estimated U$231m to Biota Pharmaceuticals (Formerly Biota Holdings Ltd) wholly owned subsidiary, Biota Scientific Management Pty Ltd, for the advanced development of Laninamivir in the US.<ref>{{Cite web |url=http://www.biotapharma.com/?page=1021001&subpage=1021019 |title=Biota Pharmaceuticals - Home |access-date=2013-04-12 |archive-date=2016-03-05 |archive-url=https://web.archive.org/web/20160305125510/http://biotapharma.com/?page=1021001&subpage=1021019 |url-status=dead }}</ref> It is under clinical evaluations in other countries.<ref name="samson review" /><ref>{{cite book | vauthors = Ishjida T | chapter = Treatment Guidelines for Influenza Virus Infection: What Does the Recent Guideline State? | veditors = Fujita J | title = Influenza: Advances in Diagnosis and Management | series = Respiratory Disease Series: Diagnostic Tools and Disease Managements. | publisher = Springer | location = Singapore | doi = 10.1007/978-981-15-9109-9_13 | isbn = 978-981-15-9109-9 | chapter-url = https://books.google.com/books?id=J0UIEAAAQBAJ&dq=Laninamivir+clinical+evaluations+in+other+countries&pg=PA132 | date = 2020 | pages = 129–136 (132) | s2cid = 228892521 }}</ref>

== References ==

{{Reflist}}

{{RNA antivirals}}

{{Influenza}}

[[Category:Guanidines]]

[[Category:Neuraminidase inhibitors]]

[[Category:Dihydropyrans]]

[[Category:Acetamides]]

{{antiinfective-drug-stub}}